188 related articles for article (PubMed ID: 12751170)
21. Incretins, insulin secretion and Type 2 diabetes mellitus.
Vilsbøll T; Holst JJ
Diabetologia; 2004 Mar; 47(3):357-366. PubMed ID: 14968296
[TBL] [Abstract][Full Text] [Related]
22. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.
Nauck MA; Baller B; Meier JJ
Diabetes; 2004 Dec; 53 Suppl 3():S190-6. PubMed ID: 15561910
[TBL] [Abstract][Full Text] [Related]
23. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1 is a physiological incretin in rat.
Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
[TBL] [Abstract][Full Text] [Related]
25. GLP-1 in NIDDM.
Holst JJ
Diabet Med; 1996 Sep; 13(9 Suppl 6):S156-60. PubMed ID: 8894501
[TBL] [Abstract][Full Text] [Related]
26. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
Gromada J; Brock B; Schmitz O; Rorsman P
Basic Clin Pharmacol Toxicol; 2004 Dec; 95(6):252-62. PubMed ID: 15569269
[TBL] [Abstract][Full Text] [Related]
27. GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse.
Fridolf T; Böttcher G; Sundler F; Ahrén B
Pancreas; 1991 Mar; 6(2):208-15. PubMed ID: 1886889
[TBL] [Abstract][Full Text] [Related]
28. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
29. [Review: regulation of glucose metabolism].
Yamada Y; Seino Y
Nihon Rinsho; 2002 Jul; 60 Suppl 7():153-8. PubMed ID: 12238041
[No Abstract] [Full Text] [Related]
30. The glucagon-like peptides: a double-edged therapeutic sword?
Perry T; Greig NH
Trends Pharmacol Sci; 2003 Jul; 24(7):377-83. PubMed ID: 12871671
[No Abstract] [Full Text] [Related]
31. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
32. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility.
Miki T; Minami K; Shinozaki H; Matsumura K; Saraya A; Ikeda H; Yamada Y; Holst JJ; Seino S
Diabetes; 2005 Apr; 54(4):1056-63. PubMed ID: 15793244
[TBL] [Abstract][Full Text] [Related]
33. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.
Orskov C; Holst JJ; Nielsen OV
Endocrinology; 1988 Oct; 123(4):2009-13. PubMed ID: 2901341
[TBL] [Abstract][Full Text] [Related]
34. Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion.
Hui H; Yu R; Bousquet C; Perfetti R
Endocrinology; 2002 Sep; 143(9):3529-39. PubMed ID: 12193567
[TBL] [Abstract][Full Text] [Related]
35. Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.
Byrne MM; Göke B
Diabet Med; 1996 Oct; 13(10):854-60. PubMed ID: 8911778
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential.
Holst JJ
Curr Med Chem; 1999 Nov; 6(11):1005-17. PubMed ID: 10519910
[TBL] [Abstract][Full Text] [Related]
37. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
Kjems LL; Holst JJ; Vølund A; Madsbad S
Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
[TBL] [Abstract][Full Text] [Related]
38. [Glucagon and GLP (glucagon-like peptide)].
Matsuyama T
Nihon Rinsho; 2002 Jul; 60 Suppl 7():246-51. PubMed ID: 12238055
[No Abstract] [Full Text] [Related]
39. The incretin notion and its relevance to diabetes.
Habener JF
Endocrinol Metab Clin North Am; 1993 Dec; 22(4):775-94. PubMed ID: 8125072
[TBL] [Abstract][Full Text] [Related]
40. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors.
Holst JJ
Adv Exp Med Biol; 2003; 524():263-79. PubMed ID: 12675249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
